4.2 Article

Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure

期刊

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
卷 24, 期 4, 页码 203-209

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RHU.0000000000000736

关键词

blood pressure; disease-modifying antirheumatic drugs; rheumatoid arthritis

资金

  1. Veterans Affairs Clinical Science Research & Development Career Development Award [IK2 CX000955]
  2. National Institutes of Musculoskeletal and Skin Disorders [1K24AR055259-01]
  3. Veterans Affairs Merit Award [CX000896]
  4. NIH/NIGMS [U54GM115458]
  5. VA HSRD IIR [14-048-3]
  6. Specialty Care Center of Innovation, Veterans Health Administration, Department of Veterans Affairs
  7. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM115458] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Purpose This study reports the effect of disease-modifying therapies for rheumatoid arthritis (RA) on systolic and diastolic blood pressure (SBP, DBP) over 6 months and incident hypertension over 3 years in a large administrative database. Methods We used administrative Veterans Affairs databases to define unique dispensing episodes of methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, tumor necrosis factor inhibitors, and prednisone among patients with RA. Changes in SBP and DBP in the 6 months before disease-modifying antirheumatic drug initiation were compared with changes observed in the 6 months after initiation. The risk of incident hypertension within 3 years (new diagnosis code for hypertension and prescription for antihypertensive) was also assessed. Multivariable models and propensity analyses assessed the impact of confounding by indication. Results A total of 37,900 treatment courses in 21,216 unique patients contributed data. Overall, there were no changes in SBP or DBP in 6 months prior to disease-modifying antirheumatic drug initiation (all P > 0.62). In contrast, there was a decline in SBP ( = -1.08 [-1.32 to -0.85]; P < 0.0001) and DBP ( = -0.48 [-0.62 to -0.33]; P < 0.0001) over the 6 months following initiation. The greatest decline was observed among methotrexate and hydroxychloroquine users. Methotrexate users were 9% more likely to have optimal blood pressure (BP) after 6 months of treatment. Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1.53 [1.21-1.91]; P < 0.001). Conclusions Blood pressure may improve with treatment of RA, particularly with methotrexate or hydroxychloroquine. Leflunomide use, in contrast, is associated with increases in BP and a greater risk of incident hypertension.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据